Glucocorticoid withdrawal and glucocorticoid-induced adrenal insufficiency: Study protocol of the randomized controlled «TOASST" (Taper Or Abrupt Steroid STop) multicenter trial.

Publikation

Wissenschaftlicher Artikel/Review - 05.04.2023

Komminoth Mathis, Donath Marc Y, Hepprich Matthias, Schuetz Philipp, Blum Claudine A, Müller-Stich Beat P, Reny Jean-Luc, Gosselin Pauline, Breville Gautier, Brändle Michael, Henzen Christophe, Leuppi Joerg Daniel, Kistler Andreas D, Thurnheer Robert, Beuschlein Felix, Rudofsky Gottfried, Aeberli Daniel, Villiger Peter M, Böhm Stephan, Chifu Irina, Fassnacht Martin, Meyer Gesine, Bojunga Jörg, Cattaneo Marco, Sluka Constantin, Schneider Helga, Rutishauser Jonas, «TOASST» study group

Zitation

Komminoth M, Donath M, Hepprich M, Schuetz P, Blum C, Müller-Stich B, Reny J, Gosselin P, Breville G, Brändle M, Henzen C, Leuppi J, Kistler A, Thurnheer R, Beuschlein F, Rudofsky G, Aeberli D, Villiger P, Böhm S, Chifu I, Fassnacht M, Meyer G, Bojunga J, Cattaneo M, Sluka C, Schneider H, Rutishauser J, «TOASST» study group. Glucocorticoid withdrawal and glucocorticoid-induced adrenal insufficiency: Study protocol of the randomized controlled «TOASST" (Taper Or Abrupt Steroid STop) multicenter trial. PloS one 2023; 18:e0281585.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

PloS one 2023; 18

Veröffentlichungsdatum

05.04.2023

eISSN (Online)

1932-6203

Seiten

e0281585

Kurzbeschreibung/Zielsetzung

Despite the widespread use of glucocorticoids in inflammatory and autoimmune disorders, there is uncertainty about the safe cessation of long-term systemic treatment, as data from prospective trials are largely missing. Due to potential disease relapse or glucocorticoid-induced hypocortisolism, the drug is often tapered to sub-physiological doses rather than stopped when the underlying disease is clinically stable, increasing the cumulative drug exposure. Conversely, the duration of exposure to glucocorticoids should be minimized to lower the risk of side effects.